Emergent BioSolutions to Release Fourth Quarter 2021 Financial Results and Conduct Conference Call on February 24, 2022
GAITHERSBURG, Md., Feb. 07, 2022 (GLOBE NEWSWIRE) --Emergent BioSolutions (NYSE: EBS) will host a conference call on Thursday, February 24, 2022 at 5:00 pm eastern time to discuss the financial results for the fourth quarter 2021, recent business developments, financial outlook for full year 2022, and revenue guidance for the first quarter of 2022.
This conference call can be accessed live by telephone or by webcast:
Teleconference Information:
Dial in number – toll-free: (855) 766-6521
Dial in number – toll: (262) 912-6157
Conference ID: 7619558
Webcast Information:
Visit https://edge.media-server.com/mmc/p/tfd93ojy for the live webcast.
A replay of the call can be accessed from the Investors page of the Emergent website.
About Emergent BioSolutions
At Emergent, our mission is to protect and enhance life. We develop, manufacture, and deliver protections against public health threats through a pipeline of innovative vaccines and therapeutics. For over 20 years, we’ve been at work defending people from things we hope will never happen—so that we’re prepared just in case they ever do. We do what we do because we see the opportunity to create a better, more secure world. One where preparedness empowers protection from the threats we face. And peace of mind prevails. In working together, we envision protecting or enhancing 1 billion lives by 2030. For more information, visit our website and follow us on LinkedIn, Twitter, and Instagram.
Investor Contact:
Robert G. Burrows
Vice President, Investor Relations
240-631-3280
burrowsr@ebsi.com
Media Contact:
Matt Hartwig
Senior Director, Media Relations
mediarelations@ebsi.com
